Communiqués Apontis Pharma AG

Actions

APPH

DE000A3CMGM5

Marché Fermé - Xetra Autres places de cotation 17:36:06 28/06/2024			Varia. 5j.	Varia. 1 janv.
8,6 ^EUR	0,00%		-0,69%	+81,05%

28/03	Apontis Pharma AG publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
28/03	Transcript : Apontis Pharma AG, 2023 Earnings Call, Mar 28, 2024

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company	27/06	EQ
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management	04/06	EQ
DD: APONTIS PHARMA AG: Thomas Milz, buy	14/05	EQ
DD: APONTIS PHARMA AG: be executive GmbH, buy	14/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
Apontis Pharma : Earnings Call Q1/24 Presentation	08/05	PU
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed	08/05	EQ
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast	05/04	EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications	05/04	EQ
APONTIS PHARMA expects profitable growth again in 2024	28/03	EQ
Apontis Pharma : Earnings Call 2023 Presentation	28/03	PU
APONTIS PHARMA successfully completes performance and efficiency improvement program	06/02	EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published	09/11	EQ
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program	08/11	EQ
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline	10/08/23	EQ
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024	31/07/23	EQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Apontis Pharma AG

Actions

APPH

DE000A3CMGM5

Communiqués

Filtres